Osivax and GC Biopharma announced a new alliance focused on developing a new-generation influenza vaccine. The vaccine will combine OVX836 and GC FLU. Osivax secured the rights to advance a combination shot.
Older adults are facing four vaccine decisions this fall, while the federal immunization calendar still carries a 2025 date. Flu and pneumonia deaths have fallen for 25 years, but one American age group posted an uptick.